Email updates

Keep up to date with the latest news and content from BMC Cancer and BioMed Central.

Open Access Highly Accessed Research article

In vitro and in vivo anticancer properties of a Calcarea carbonica derivative complex (M8) treatment in a murine melanoma model

Fernando SF Guimarães1, Lucas F Andrade1, Sharon T Martins1, Ana PR Abud1, Reginaldo V Sene1, Carla Wanderer1, Inés Tiscornia2, Mariela Bollati-Fogolín2, Dorly F Buchi1 and Edvaldo S Trindade1*

Author Affiliations

1 Laboratório de Pesquisa em Células Inflamatórias e Neoplásicas Depto de Biologia Celular, Setor de Ciências Biológicas, Federal University of Paraná, Brazil

2 Cell Biology Unit (CBU), Institut Pasteur de Montevideo (IPMon), Uruguay

For all author emails, please log on.

BMC Cancer 2010, 10:113  doi:10.1186/1471-2407-10-113

Published: 25 March 2010

Abstract

Background

Melanoma is the most aggressive form of skin cancer and the most rapidly expanding cancer in terms of worldwide incidence. Chemotherapeutic approaches to treat melanoma have had only marginal success. Previous studies in mice demonstrated that a high diluted complex derived from Calcarea carbonica (M8) stimulated the tumoricidal response of activated lymphocytes against B16F10 melanoma cells in vitro.

Methods

Here we describe the in vitro inhibition of invasion and the in vivo anti-metastatic potential after M8 treatment by inhalation in the B16F10 lung metastasis model.

Results

We found that M8 has at least two functions, acting as both an inhibitor of cancer cell adhesion and invasion and as a perlecan expression antagonist, which are strongly correlated with several metastatic, angiogenic and invasive factors in melanoma tumors.

Conclusion

The findings suggest that this medication is a promising non-toxic therapy candidate by improving the immune response against tumor cells or even induce direct dormancy in malignancies.